Statements (87)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:chemicalFormula |
C20H25N3O2S
|
| gptkbp:currentCondition |
major depressive disorder
|
| gptkbp:hasCitations |
antidepressant
|
| gptkbp:hasFilm |
dizziness
nausea |
| gptkbp:hasMerchandise |
serotonin reuptake inhibition
|
| gptkbp:hasResearchInterest |
Journal of Medicinal Chemistry
|
| gptkbp:hasWeight |
375.50 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRP-9019
|
| gptkbp:isAssociatedWith |
therapy sessions
serotonin syndrome |
| gptkbp:isAttendedBy |
psychotherapy
clinical settings oral tablet lifestyle modifications supportive therapy outpatient settings healthcare_professionals clinical trials phase II integrated care settings |
| gptkbp:isConsidered |
combination therapy
community mental health programs preventive treatment integrative treatment approaches dual diagnosis treatment holistic treatment options first-line treatment off-label use treatment-resistant depression |
| gptkbp:isEngagedIn |
clinical trials
|
| gptkbp:isEvaluatedBy |
patient compliance
treatment efficacy patient satisfaction therapeutic outcomes safety profile functional outcomes |
| gptkbp:isImportantFor |
quality of life
weight gain |
| gptkbp:isInformedBy |
excipients
|
| gptkbp:isKnownFor |
improving mood
|
| gptkbp:isPartOf |
clinical guidelines
evidence-based practices SSRIs clinical research studies mental health research initiatives clinical trials registry SRP drug portfolio mental health care strategies mental health pharmacotherapy mental health treatment protocols |
| gptkbp:isPortrayedBy |
rapid onset of action
well-tolerated favorable tolerability low abuse potential |
| gptkbp:isProtectedBy |
yes
|
| gptkbp:isReflectedIn |
emotional well-being
symptom relief |
| gptkbp:isRelatedTo |
serotonin receptors
|
| gptkbp:isStudiedIn |
animal models
anxiety disorders bipolar disorder social anxiety disorder post-traumatic stress disorder substance use disorders eating disorders obsessive-compulsive disorder psychosomatic disorders |
| gptkbp:isSubjectTo |
regulatory approval
|
| gptkbp:isSupportedBy |
psychological resilience
|
| gptkbp:isUsedIn |
mental health treatment
pharmaceutical research |
| gptkbp:isUtilizedFor |
emotional regulation
cognitive function sleep disorders behavioral health issues chronic pain management long-term effects neuroprotective effects psychotic disorders mood stabilization co-morbid conditions |
| gptkbp:isUtilizedIn |
case studies
randomized controlled trials longitudinal studies real-world settings |
| gptkbp:isVisitedBy |
gptkb:SR_Pharmaceuticals
|